Document:

EX-10.13

 Exhibit 10.13 

Certain identified information marked with [***] has been excluded from this exhibit because it is not 

material and is of the type that the registrant treats as private and confidential. 

Vendor Agreement 
 Between

 Thorne Research, Inc. 
 And

 BioTE Medical, LLC 

December 1, 2020 

  
 1 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 VENDOR AGREEMENT 

This Vendor Agreement (“this Agreement”) is made and entered into as of the 1st day of December 2020 (“the Effective Date”), by and
between Thorne Research, Inc., a South Carolina corporation (“Thorne”), having its offices at 620 Omni Industrial Blvd., Summerville, South Carolina 29486, and BioTE Medical, LLC, a Texas limited liability company (“BioTE”),
having its offices at 1875 West Walnut Hill Lane, Suite 100, Irving, Texas 75038, and who are sometimes referred to individually as a “Party” or together as the “Parties.” 

WHEREAS, the Parties entered into that certain Non-Exclusive
Co-Marketing Agreement, dated May 30, 2019, but the Parties now desire to replace that agreement with the terms, conditions, and obligations of this Agreement; and 

WHEREAS, Thorne intends to provide product and AgeBio testing of up to [***] toward the funding of a clinical trial to be sponsored by and conducted by
BioTE and Thorne; and 
 WHEREAS, Thorne remains engaged in the business of research, development, manufacture, distribution, and sale of a line of
nutritional supplement products that promote better health and wellbeing for patients through health-care practitioners who prescribe or recommend Thorne’s nutritional supplement products to their patients; and 

WHEREAS, BioTE remains engaged in the business of recruiting, training, and supporting physicians and other healthcare providers located in the United
States of America or any of its territories to perform BioTE’s proprietary method of hormone balance (“BioTE Medical Hormone Pellet Therapy”) using pelletized therapeutic products derived from natural plant sources designed to
replicate the body’s normal hormonal levels; and 
 WHEREAS, BioTE commits to a long-term strategic partnership with Thorne to grow the
supplements and wellness products offering for BioTE’s 5,500 practitioners in the U.S. BioTE also commits to work with Thorne to provide supplements for BioTE’s currently unserved international practitioners. BioTE has invested
considerable funds and will continue to invest funds creating a market for these Thorne supplements in the clinical, retail, direct to consumer, and online markets in Mexico and South America. 

WHEREAS, BioTE currently sells only to medical practitioners, BioTE is making a considerable investment in adding direct-to-patient and direct-to-consumer supplement sales. All Thorne-BioTE products will be marketed to these large new markets
in Q1 2021. Although BioTE’s growth with Thorne has been strong in the practitioner market, it will only be a fraction of the new direct-to-patient and direct-to-consumer market. Considerable growth can also be predicted on the automatic delivery/subscription service that will be available at the start of the program in Q1
2021. 

  
 2 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 WHEREAS, BioTE will continue to use Thorne as a contract manufacturer for the current BioTE-labelled
nutritional supplement products listed in Appendix 1, and as mutually agreed on for future nutritional supplement product development and manufacturing for BioTE-labelled nutritional supplement products and, where appropriate and mutually agreed on,
recommend Thorne’s nutritional supplement product line to those health-care practitioners who prescribe and recommend the BioTE Medical Hormone Pellet Therapy to their patients. 

NOW THEREFORE, the Parties agree on the following terms, conditions, and obligations as set forth herein: 

 

	1.	 Validation Study. The Parties anticipate that certain of BioTE’s certified healthcare providers
will conduct a year-long validation study. The Parties further anticipate that Thorne will provide up to, but not more than, [***] in product and AgeBio Testing toward implementing and conducting the validation study. The Parties agree to provide an
appropriate attribution to Thorne’s participation and assistance in the validation study upon publication of the results of such study. 

  

	2.	 Term. Whereas the initial term of the Non-Exclusive Vendor
Agreement was two (2) years; i.e., the term of that agreement would have expired on May 29, 2021, the initial term of this Agreement will be three (3) years; i.e., the expiration date of this Agreement will be November 30, 2023;
provided, however, that either Party may terminate this Agreement at any time for business convenience by providing a 180-day written notice to the other Party. 

 

	3.	 Drop Ship Agreement. The Parties agree that certain Drop Ship Agreement previously agreed to and
executed by the Parties on May 30, 2019 (Appendix 2) will remain in place, and the Parties agree to continue to comply with its terms, conditions, and obligations, and such Drop Ship Agreement is incorporated by reference herein.
Notwithstanding the foregoing, the Parties agree that if BioTE moves from a drop ship arrangement to an agreement with a third-party logistics provider, the Parties will review and revise the Drop Ship Agreement in place to address such change in
shipping arrangements. 

  

	4.	 Quality Agreement. The Parties agree to the terms, conditions, and obligations of the Quality Agreement
attached as Appendix 3, below, which is executed by the Parties as of the Effective Date of this Agreement and is incorporated by reference herein. 

  

	5.	 Sales Strategies. The Parties agree to continue to use commercially reasonable efforts by Thorne’s
sales representatives to expose, instruct, and recommend the BioTE Medical Hormone Pellet Therapy to their health-care practitioner customers, and by BioTE to expose, instruct, and recommend BioTE-branded and Thorne’s nutritional supplement
product line to BioTE’s health-care practitioner customers. 

  
 3 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	6.	 Sales and Marketing Materials. The Parties agree to work together to develop sales and marketing
materials to be used by Thorne and BioTE, respectively, to facilitate the accomplishment of the Sales Strategies set forth in Paragraph 5, above. 

  

	7.	 Training. The Parties agree to make training available to each Party’s respective sales force.

  

	8.	 Commission Structure. Thorne agrees that if any of BioTE’s customers opt to purchase any other non-BioTE branded products, then BioTE will be entitled to receive a [***] commission paid for on a monthly commission cycle for the other products sold, but not including previous Thorne customers who have
purchased product from Thorne in the previous 24 months. 

  

	9.	 Contract Manufacturing. The Parties agree that during the Term of this Agreement, Thorne will continue
to be a manufacturer of the finished nutritional supplement products that bear a BioTE-branded label listed in Appendix 1, subject to the mutually agreed upon production schedule(s) for the manufacture of such products. BioTE further agrees to
continue to purchase such finished products from Thorne as set forth in this Agreement at such time as each lot of finished product is released for sale by Thorne’s Quality Assurance/Quality Control Department, and proof of such release for
sale of finished BioTE-branded product is submitted, with the lot number’s accompanying invoice, to BioTE for approval and payment. BioTE will continue to receive a weekly statement reconciling the previous week’s orders processed by
Thorne, which statement will continue to be emailed to BioTE each week for the previous week’s processed orders. BioTE will continue to receive a [***] discount for payment of a statement within seven (7) days or less from the date of the
statement received and be allowed to pay their invoice by credit card. BioTE will continue to have up to seven (7) days to review the statement for accuracy and make payment by credit card on or before the seventh day to receive the 1-percent early payment discount. If payment is not received by the seventh day after a statement is received by BioTE, then Thorne can seek approval from BioTE to charge BioTE’s credit card on file without a
discount. In the event Thorne experiences an increase greater than ten percent (10%) in raw material or component costs for those items needed in order to manufacture the finished nutritional supplement products for BioTE, Thorne may, upon receipt
of BioTE’s prior written approval, which approval will not be unreasonably withheld, increase the purchase price of the finished nutritional supplement products manufactured for BioTE. 

 

	10.	 Stock. Subject to reasonably accurate and timely rolling
12-month forecasts from BioTE, as well as mutually agreed upon production schedule(s), Thorne continues to commit to remain in stock on those BioTE-branded products manufactured pursuant to Paragraph 9, above.
Thorne agrees to provide written notice to BioTE immediately (i.e., within twenty- four (24) business hours) if an out-of-stock situation occurs, and Thorne agrees
to continue to pay for additional 2-day shipping at no cost to the customer or BioTE. 

  
 4 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	11.	 Tracking and Billing. As the Parties deem necessary and by mutual agreement, the Parties agree to
continue to develop processes to track and report the purchases of Thorne’s nutritional supplement products that are consummated as a result of the implementation of the Sales Strategies contemplated in Paragraph 5, above.

  

	12.	 Nutritional Supplement Products. The Parties agree that as of the Effective Date of this Agreement the
nutritional supplement products that BioTE will expose to, instruct on, and recommend to their health-care practitioner customers are those listed in Appendix 1. By mutual agreement, the Parties reserve the right to add additional nutritional
supplement products during the Term of this Agreement. 

  

	13.	 Forecasts. Thorne and BioTE will continue to work closely together, and in good faith, to put in place
rolling 12-month quarterly forecasts for production, which will be updated bimonthly based on historic and future trends. 

 

	14.	 Shipping / Returns. Thorne’s modified shipping rates as agreed on by the Parties in Appendix 2 of
the previous Non-Exclusive Vendor Agreement will continue to apply as the shipping rates during the Term of this Agreement, and former Appendix 2 is incorporated by reference herein as Appendix 2. Returns will
continue to be addressed by the Parties on a case-by-case basis. 

  

	15.	 No Representations or Warranties. Neither Thorne nor BioTE are authorized to make representations or
warranties on behalf of the other with respect to the BioTE Medical Hormone Pellet Therapy or Thorne’s nutritional supplement products, respectively, that are not otherwise contained in the sales and marketing materials contemplated by
Paragraph 6, above, or otherwise authorized by the prior written consent of the Party for whom the representation or warranty might apply. 

  

	16.	 Regulatory Compliance and Oversight. Each Party will be solely responsible for its compliance with the
applicable laws and regulations pertaining to the manufacture, marketing, and distribution of its products and services. 

  

	 	(a)	 Thorne will be responsible for adverse event reporting for the Thorne nutritional supplement products that
BioTE recommends to its affiliated providers. 

  

	 	(b)	 Thorne will be responsible for complying with the regulatory requirements, policies, and procedures associated
with manufacturing, distributing, and marketing its nutritional supplement product line. 

  

	17.	 Product Discontinuance. Either Party may discontinue at any time, with at least one hundred twenty
(120) days’ prior written notice to the other Party, any product. In the event BioTE discontinues a BioTE-branded product, then BioTE will be obligated to purchase, within one hundred eighty (180) days, any inventory of that
discontinued product existing as of the date BioTE provided written notice of discontinuance. 

  
 5 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	18.	 Force Majeure. Except for payments due under this Agreement, neither Party will be responsible for any
failure to perform or delay in performance if such failure or delay is caused, directly or indirectly, by events or circumstances beyond such Party’s reasonable control (each a “Force Majeure”), including, but not limited to, acts of
God, war, sabotage, riot, embargoes, compliance with court orders, acts of civil or military authorities, domestic or foreign acts of terrorism, denial of or delays in processing of export license applications, fire, lightening, epidemic, pandemic,
floods or other severe weather conditions, earthquakes, accidents, strikes, fuel crises, interruptions or delays in transportation or communication facilities, or any other event or circumstance, whether similar or dissimilar to those set forth
herein, provided that such Party gives prompt written notice thereof to the other Party and takes reasonable steps to minimize the effect of the event on such Party’s performance. The time for performance will be extended for a period equal to
the duration of the Force Majeure, but in no event longer than sixty (60) days. After such time, the other Party will have the right to immediately terminate this Agreement. 

 

	19.	 Indemnification. Each Party agrees to indemnify the other Party and hold it harmless from all claims,
demands, damages, and liabilities of any kind to the extent any such claim, demand, damage, or liability arises as a result of the implementation of their respective obligations undertaken by the Parties in the performance of this Agreement.

  

	20.	 Intellectual Property; BioTE’s customers. The Parties acknowledge that each Party exclusively owns
the right, title, and interest in its respective intellectual property, and that nothing in this Agreement transfers or inhibits the other Party’s exclusive ownership thereof. Without limiting the generality of the foregoing, the Parties agree
that any proprietary formulations developed by BioTE will remain the sole and exclusive property of BioTE, regardless of whether BioTE utilizes Thorne to manufacture or produce any such products on BioTE’s behalf. Thorne acknowledges that the
customers that it ships to on behalf of BioTE are part of BioTE’s intellectual property. Thorne further acknowledges and agrees that it must obtain BioTE’s written approval prior to marketing any products, services, or items to
BioTE’s customers. As used in this Paragraph 20, the term “marketing” will include, without limitation, electronic messaging, text messaging, telephone calls, in-person meetings, mailings, the
gifting of samples, and any other advertising or soliciting of BioTE’s customers by Thorne. Notwithstanding the foregoing, this prohibition does not include previous Thorne customers who purchased product from Thorne in the twenty-four
(24) month period prior to the effective date of the Parties’ previous Non-Exclusive Vendor Agreement. 

  

	21.	 Confidentiality. The Parties agree that neither Party will disclose or use, without the other
Party’s prior written consent, any non-public, confidential, or proprietary information of the other Party, including, but not limited to, trade secrets, product development information, business
operations information, or customer information, that has been provided to the other Party in furtherance of undertaking their respective obligations. 

  
 6 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	22.	 Notices. Any notice required or desired to be given pursuant to this Agreement will be deemed to have
been given when such notice, in writing, is delivered to the other Party at the respective address first written above and addressed to the individual undersigned below. 

 

	23.	 Relationship of the Parties. Nothing contained in this Agreement will be construed as creating a joint
venture, partnership, or agency relationship between the Parties, nor will either Party have the right, power, or authority to create any obligation or duty, express or implied, on behalf of the other Party. 

 

	24.	 Governing Law. The Parties agree that this Agreement will be governed by the laws of the State of
Delaware, without regard to Delaware’s rules relating to conflicts of laws, and the Parties hereby consent to the jurisdiction of the federal and state courts of the State of Delaware relating to any action, suit, or proceeding brought to
compel performance of any obligation undertaken herein by the Parties. 

  

	25.	 Entire Agreement; Amendments. This Agreement and attached Appendices, and the documents incorporated by
reference in this Agreement, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements between the Parties with respect to its subject matter. No amendment, change, waiver, or
discharge hereof will be valid unless in writing and signed by the Party against which such amendment, change, waiver, or discharge is sought to be enforced. 

[SIGNATURE PAGE FOLLOWS] 

  
 7 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 IN WITNESS WHEREOF, the Parties have executed this Vendor Agreement as of the Effective Date above
written. 
  

	
	FOR THORNE RESEARCH, INC.
	
	/s/ Paul F. Jacobson
	By:   Paul F. Jacobson
	Its:    Chief Executive Officer
	
	FOR BIOTE MEDICAL, LLC
	
	/s/ Terry Weber
	By:   Terry Weber
	Its:    Chief Executive Officer

  
 8 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 1 

Current BioTE-labelled Nutritional Supplement Products 

Methyl Guard Plus 
 Meriva 500
SF 
 DIM SGS + 
 ADK 5 

ADK 10 
 FloraSport Probiotic

 Iodine 
 Omega w/CoQ10 

Bacillus Coagulans 

  
 9 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 2 

Shipping Provisions 
 All shipping of BioTE
products will be coordinated through Thone’s Shipping Department, who will be responsible for determining and administering the most cost-effective and timely means of transit. 

Orders will be processed for fulfillment from 8:30 am to 7:00 pm ET (4 pm PT). 

Within the continental U.S., the following shipping terms will apply: 
  

	 	●	 	 Free shipping (delivery within 1 to 3 business days of order) for any order of 1 case or more.

  

	 	●	 	 1-day air will be billed to BioTE at [***] per shipment.

 Shipments to Hawaii will be billed to BioTE at [***], with delivery being 3 business days from
pick-up. 
 The Shipping Department will also coordinate International shipments as required. 

 

	 	●	 	 For Canada — BioTE will be charged [***] per shipment with delivery within 3 business days of order.

  

	 	●	 	 For Puerto Rico, the U.S. Virgin Islands and other Caribbean locations — BioTE will be charged [***] per
shipment with delivery within 3 business days of order. 

 Discounts for Order Processing for BioTE 3PL 

During the term of this agreement, if and when BioTE elects uses their own third party logistics provider (3PL) for order fulfillment, Thorne agrees to a [***]
per bottle discount as Thorne will no longer be required provide order processing (pick-pack-ship) direct to Clinics or Patients, and only ship in bulk quantities to the selected BioTE 3PL. 

  
 10 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 3 

Quality Agreement 
 This Quality Agreement
(“this Agreement”) is made as of the 1st day of December 2020, by and between: 
 Thorne Research, Inc. (“Thorne”)
having a principal place of business at 620 Omni Industrial Blvd., Summerville, South Carolina 29486, with an FDA Food Facility Registration Number of 11647265648, 

and 
 BioTE Medical, LLC
(“BioTE”) having a principal place of business at 1875 West Walnut Hill Lane, Suite 100, Irving, Texas 75038. 
 WHEREAS,
BioTE has contracted with Thorne to provide manufacturing services in respect of certain Products (as set forth in Exhibit 1 of this Agreement) (the “Products”); and 

WHEREAS, the parties desire to allocate the responsibility for procedures and Specifications, as defined below in Section 1.1 and set out
in Exhibit 1 herein, impacting on the identity, strength, quality, and purity of the Products. 
 NOW THEREFORE, in consideration for the
promises and agreements contained herein, the parties agree as follows: 
  

	1.0	 GENERAL REQUIREMENTS 

 

	1.1	 Specifications 

Both parties acknowledge that Thorne’s and BioTE’s businesses and operations are regulated by the U.S. Food and Drug Administration
(“FDA”) and therefore agree to comply with the requirements of this Agreement and the Specifications. For purposes of clarity, the terms and conditions of this Agreement will apply to the Products set forth in Exhibit 1, as well as any
future products manufactured by Thorne on behalf of BioTE. 
  

	1.2	 Division of Responsibilities 

This Agreement defines the responsibilities of Thorne and BioTE for assuring compliance with current Good Manufacturing Practices (21 CFR Part
111), and quality activities associated with production, packaging, testing, and release of Products (“cGMPs”). 

  
 11 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	1.3	 Business Terms 

This Agreement does not define the business terms relating to the commercial supply of Products. To the extent there is conflict or
inconsistency between the provisions of this Agreement and a BioTE purchase order and/or the Non-Exclusive Co-Marketing Agreement between Thorne and BioTE, the terms of
the Purchase Order and/or such Non-Exclusive Co-Marketing Agreement will govern with respect to the terms and conditions relating to the business and commercial supply
requirements for Products. 
  

	1.4	 Attached Exhibits 

Listed below are the following Exhibits that are attached hereto and incorporated into this Agreement: 

Exhibit 1 — Products and Specifications 
  

	2.0	 REGULATORY COMPLIANCE 

 

	2.1	 Product and Facility Compliance 

Thorne will itself manufacture, except for as set forth in Section 15.0, Products in accordance with the requirements of cGMPs. 

Thorne will conduct manufacturing operations in accordance with current cGMP guidelines and accepted industry practices during the term of this
Agreement. These requirements include maintaining a quality assurance system and facility that complies with and satisfies the requirements of 21 CFR Part 111, or an equivalent standard, where applicable, for any electronic records and computer
systems. 
 Thorne and BioTE are responsible for complying with the regulatory requirements that are specifically set forth in this Agreement
or the Division of Responsibilities. 
  

	2.2	 Compliance: Audits 

Thorne may be periodically audited upon reasonable notice by BioTE or an approved BioTE agent for compliance to current cGMPs and BioTE
requirements and to assess the effectiveness of Thorne’s quality system. Thorne will allow BioTE reasonable access to the facility, to appropriate personnel, and to relevant documents, including laboratory testing notebooks. The cost of such
audit will be borne by BioTE. Trade secret documents that relate to formulas and manufacturing processes will need approval from Thorne’s Chief Operating Officer prior to sharing documents with BioTE. Documents will not be transmitted
electronically, but can be viewed as hard copies during compliance audits. 

  
 12 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	2.3	 FDA Food Facility Registration 

Thorne is responsible to register its manufacturing facility with the FDA and to maintain the registration documents such that they are readily
available for inspection, as the case may be. 
 Thorne’s current FDA Food Facility Registration Number is 11647265648. 

 

	2.4	 Regulatory Inspections 

Thorne will notify BioTE’s Quality Control of any regulatory inspections and state or federal correspondence (which include, but are not
limited to, FDA Form 483s, FDA Warning Letters, and FDA or state board inspection reports, among others) concerning Product quality within three (3) business days or sooner. Thorne will also provide a copy of any such inspection reports or
copies of any correspondence received from state or federal regulators to BioTE within three (3) business days or sooner per lawyer client privileges. 

BioTE will notify Thorne of any regulatory inspections that BioTE is subject to that implicate Thorne or involve any of Thorne’s products
manufactured under BioTE’s label, and Thorne agrees to be immediately available by telephone to provide any appropriate documentation that BioTE will need to satisfy the inspection. BioTE to provide a copy of inspection reports related to
Thorne manufactured products within three business days of receiving the final report. 
  

	2.5	 Qualifications and Training 

Procedures will be established by Thorne to assure that all personnel are adequately educated and routinely trained according to cGMP regulations and job
functions. 
 Thorne will maintain and record training documents, and will provide evidence of personnel qualification and routine training to BioTE
immediately upon request. 
  

	3.0	 CONTROL DOCUMENTATION AND CHANGE CONTROL 

 

	3.1	 Control Documentation 

Thorne will maintain on site a system of written quality procedures, manufacturing instructions, and facility operations that reflect the
processes set forth in the specifications. In addition, Thorne will, in accordance with cGMPs, maintain a change management system that tracks and controls changes to such documents. 

  
 13 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	3.2	 Change Control 

Thorne will provide BioTE with at least thirty (30) days’ prior written notice of any significant changes that have potential effects
on the quality and/or marketing authorization of the products listed within this document. Change requests will confirm that product characteristics will be unaffected and will be supported by technical documentation. Significant changes to product
manufacturing or packaging processes, equipment, production sites, tests, or specifications that would require regulatory approval or notification must be mutually agreed upon in writing by Thorne and BioTE. 

The parties mutually agree to make changes to the Products and Specifications (as listed on Exhibit 1) to comply with cGMPs or any governmental
guidelines. Thorne agrees to implement any changes to the extent such changes are necessary to comply with cGMPs and any governmental guidelines. 
  

	3.3	 Other Changes 

Thorne will provide at least thirty (30) days’ prior written notice to BioTE of any proposed changes relating to the storage or
shipment of Products, as well as any planned changes in any facilities or equipment that may impact the manufacturing of Products. 
  

	4.0	 CERTIFICATE OF ANALYSIS AND CERTIFICATE OF COMPLIANCE 

 

	4.1	 Certificate of Analysis 

Thorne will maintain Certificates of Analysis (“COA”) for each batch of Product delivered, and will make such COAs available to BioTE
upon request. In accordance with 21 CFR § 111.75, BioTE will rely on the information provided in the COA provided that: 
  

	 	(a)	 Thorne qualifies the supplier by establishing the reliability of the supplier’s certificate of analysis
through confirmation of the results of the supplier’s tests or examinations; 

  

	 	(b)	 The COA includes a description of the test or examination method(s) used, label claim specifications, and
actual results of the tests or examinations; 

  

	 	(c)	 Thorne maintains documentation of how Thorne qualified the supplier, and forwards such documentation to BioTE
upon BioTE’s request; 

  

	 	(d)	 Thorne periodically re-confirms the supplier’s COA; and

  

	 	(e)	 Thorne’s quality control personnel reviews and approves the documentation setting forth the basis for
qualification (and re-qualification) of any supplier. 

  
 14 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 The COA must specify the Product, specifications, including (if available) label claim,
expiration date, and results for the particular lot, and when applicable will include test method reference and the signature of the person authorized to release the lot. Thorne will provide copies of internal and external test data sheets and
chromatograms for applicable analytical tests on request for investigations or as necessary. 
 Thorne will include with the COA any record
of investigation report prepared in response to an unplanned deviation or out-of-specification test result. 

 

	4.2	 Thorne Information 

Thorne will identify knowledgeable and qualified professionals readily accessible who will provide information and respond to queries, as
follows: 
  

	 	(a)	 Notify BioTE in writing of any regulatory agency communications or contacts related to the Products and provide
a copy of documents requested and left by the authorities within one (1) business day. 

  

	 	(b)	 Notify BioTE in writing of stability trends or non-conformance to
specification within three (3) business days. 

  

	 	(c)	 Provide an investigation report for adverse events within 30 business days of Thorne’s receipt of such
complaints, or immediately upon completion of the investigation report, whichever is sooner. 

  

	 	(d)	 Meet with BioTE, as necessary, to discuss technical matters relating to the manufacture of Products.

  

	 	(e)	 Advise BioTE in writing of major unplanned process deviations or confirmed out-of-specification results within one (1) business day of Thorne’s knowledge of the same. 

  

	 	(f)	 Provide a COA (via electronic mail to BioTE’s QA department) for each finished batch shipment of Product.

  

	5.0	 INVESTIGATIONS OF DEVIATIONS 

 

	5.1	 Deviations 

Thorne will investigate thoroughly any unplanned deviation from approved procedures or out-of-specification test results, or any deviation that results from noncompliance with 21 C.F.R. § 101.9(g)(4)(i), that is, a deviation that results when the nutrient content of the composite is not
formulated to be at least equal to the value for that nutrient declared on the product’s label. Such investigation must adhere to an approved written procedure and be documented. Review and approval of such investigation by Thorne’s
Quality Assurance is required prior to disposition or disposal of the Product, if required and necessary. No Product involved in an investigation may be distributed or released to BioTE until the investigation is completed. 

  
 15 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	5.2	 Notification and Report 

Thorne must inform BioTE in writing of any major planned deviation, major unplanned deviation, or confirmed out-of-specification result affecting a Product’s quality after manufacturing or packaging, and submit to BioTE an investigation plan prior to completion of the investigation. Examples of situations that
require an investigation and report include: (i) Confirmed out-of-specification laboratory result; (ii) major process deviation; (iii) failure of
equipment that affects a Product; and (iv) significant yield deviation in or between bulk, packaged Product, and labeling. 
 A report
on root cause of the problem and corrective action/preventative action plan is due within thirty (30) calendar days of the discovery of any major process deviation or confirmed out of specification result. 

 

	6.0	 PRODUCT TESTING 

 

	6.1	 Written Procedures 

Thorne will have and follow written procedures in place for sampling and testing each batch of the Product prior to release. Such procedures
include the following: 
  

	 	(a)	 Examination of a representative sample of units during packaging operations for correct labeling.

  

	 	(b)	 Laboratory test records for conformance to Specifications, including identity, strength, purity, and potency of
selected dietary ingredients. 

  

	 	(c)	 Current and approved validated test methods and acceptance criteria at the end of manufacturing.

  

	 	(d)	 Sampling plans based on commonly accepted statistical criteria. 

Upon request, Thorne will provide BioTE with written procedures for samples and testing the product. Thorne will allow BioTE the opportunity to
request different and/or additional sampling and product testing only for investigation purposes 

  
 16 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	6.2	 Approval by a Qualified Professional 

No batch of Product will be released to BioTE prior to approval by a qualified professional. Thorne will appoint a qualified professional who
will ensure that Products meeting BioTE’s Specifications are released to BioTE. 
  

	7.0	 OBSOLETE, WASTE, AND REJECTED MATERIALS DISPOSITION 

 

	7.1	 Destruction Procedures 

Thorne will certify destruction of any excess, expired, obsolete, or rejected Products or raw materials. Thorne will provide a Certificate of
Destruction attesting that such Products or materials were destroyed at BioTE’s request (“COD”). 
  

	7.2	 Environmental Laws 

Thorne will comply with federal, state, and local applicable environmental and safety laws and regulations pertaining to handling of any waste
arising from the manufacture of Products. 
  

	8.0	 PRODUCT COMPLAINT MANAGEMENT 

Thorne will comply with all review and investigation process requirements as set forth in the sections below and in 21 CFR 111. 

 

	8.1	 Product Complaints 

Thorne or BioTE may be notified of complaints received by customers or consumers of the Product. For purposes of this Agreement, “Routine
Complaints” include any complaint that is not life threatening and includes, without limitation, short product count, incorrect address, and delayed shipments. If and when Thorne or BioTE receives a Routine Complaint, the receiver of such a
Routine Complaint must notify the other party within 72 hours, unless such complaint is an Urgent Complaint as defined below. These include complaints received either verbally or in a written format for both Urgent Complaints and Routine Complaints.

 For purposes of this Agreement, “Urgent Complaints” include any complaint that alleges an adverse event; adulteration,
contamination, tampering, misbranding, mislabeling, lack of stability, or that may reasonably be interpreted as having significant safety or regulatory consequences. With respect to Urgent Complaints, Thorne will notify BioTE of receipt of an Urgent
Complaint immediately, and not less than 24 hours after receipt. Further, Thorne will respond to BioTE inquiries in writing immediately upon BioTE’s receipt of an Urgent Complaint, and not less than 24 hours after receipt. 

  
 17 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	8.2	 Procedures for Complaints 

The procedures for handling Product complaints must address recording, managing, and investigating complaints, and the party responsible for
recording, reporting, and investigating Product complaints will forward such Product complaints to the other party. 
 Thorne will comply
with all reasonable requests made by BioTE in connection with a Product complaint, the procedures for managing Product complaints, and the investigation thereof of any Product. 

 

	8.3	 Maintaining Records 

A written record of each Product complaint will be received and maintained in accordance with cGMPs, FDA guidelines, and Thorne’s policy
for handling Product complaints. A reasonable attempt should be made to obtain and document the following information on each Product complaint record: 
  

	 	(a)	 Complainant’s name and address, unless the complainant wishes to remain anonymous. 

 

	 	(b)	 Name, strength and dosage form of the Product. 

 

	 	(c)	 Lot number and expiration date. 

 

	 	(d)	 Date complaint received and Product returned. 

 

	 	(e)	 Nature of the complaint. 

 

	 	(f)	 Complaint tracking (identification) number. 

 

	8.4	 Storage of Product Returned 

BioTE samples that contain Product (“BioTE Samples”) will be provided by BioTE to Thorne for purposes of complaint investigations, if
available. 
 Thorne will document receipt of BioTE Sample(s) in the complaint record and will maintain BioTE Samples in a secure location.

  

	8.5	 Investigation 

All Routine and Urgent Complaints received by either BioTE or Thorne regarding any of the Products require an investigation. For Routine and
Urgent Complaints, the investigation plan, outline, or list of action steps must be submitted to BioTE. The investigations may be wholly or partially executed by Thorne but must minimally include provisions for: 

  
 18 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	 	(a)	 Manufacturing record review. 

 

	 	(b)	 In-Process and Finished Product test results review.

  

	 	(c)	 Shipping and distribution controls review. 

 

	 	(d)	 Packaging record review. 

 

	 	(e)	 Review of complaint and associated files for detection of trends. 

 

	 	(f)	 Review of impact on other Product or additional lots of the same Product. 

 

	 	(g)	 Testing of returned or reserve Product as necessary. 

Investigations on Urgent Complaints will be initiated immediately with a target completion date of seven (7) calendar days. An
investigation report must be issued inclusive of results of all testing performed, data reviews, and trend discoveries, with a conclusion and corrective action/preventative action plan recommendations, as required, at the close of an investigation.
A copy of the final report must be kept on file by Thorne as part of the complaint record. Final investigation reports must be forwarded to BioTE within three (3) business days of completion. 

Product testing on returned or retained samples in the custody of Thorne is at the discretion of Thorne. BioTE may request that Thorne perform
Product testing; however, Thorne will follow its own written procedures for testing returned or retained samples. Any returned or retained samples sent to Thorne not consumed by required testing will be returned to BioTE. 

 

	9.0	 RECALL 

Thorne will have sole responsibility for initiating and managing any recall of BioTE’s Products manufactured or procured by Thorne. BioTE will be
informed prior to the initiation of a recall to the extent that such recall arises out of a breach of its obligations hereunder. 
 There will be timely
exchange of information between Thorne and BioTE about any potential recall, as follows: 
  

	 	(a)	 Thorne will immediately inform BioTE in writing of any circumstances that have come to its attention that may
make a recall necessary. 

  

	 	(b)	 In the event a Regulatory Authority issues or requests a recall, Thorne or BioTE will, within 24 hours, notify
the other party. 

  
 19 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	 	(c)	 Within 48 hours of learning that a recall may be necessary, Thorne and BioTE will discuss details of the recall
strategy. 

 BioTE will require a COD should Product be returned to Thorne as the result of a recall. 

Thorne will pay BioTE all reasonable, out-of-pocket, costs, expenses, and
attorneys’ fees borne by BioTE in connection with any recall of Thorne’s products manufactured under BioTE’s label, or in connection with any recall of product whose manufacturing process was outsourced by Thorne but bearing
BioTE’s label. 
  

	10.0	 RECORDS AND RETAINED SAMPLES RETENTION 

Thorne will hold, in a secure manner, original records and representative samples from the manufacture and control of each lot of Product. Product samples
must be stored under controlled and labeled conditions. All production history documentation will be available to BioTE for inspection while onsite. Electronic records will satisfy the requirements of 21 CFR Part 111 or an equivalent standard, where
applicable. 
  

	10.1	 Retained Samples 

Retained samples to be kept per Thorne’s internal procedure and will be provided to BioTE upon BioTE’s request. 

 

	10.2	 Records 

Thorne to follow internal document retention schedule per policy document POL-00001. 

 

	11.0	 REPROCESSING/ REWORKING 

The parties will mutually agree in advance of plans to rework or reprocess Product unless an already agreed on procedure exists and there are no trends, or as
permitted by the terms set forth in this Section. No change will be made to a validated process without the prior written authorization of BioTE. Thorne may not reprocess Product, unless reprocessing to correct defects of the type that from time to
time arise during a packaging run (e.g., jams which damage secondary packaging) due to machine capabilities. Such routine reprocessing must be documented in the packaging record. 

Thorne will have written procedures that describe the system for reworking or reprocessing Product. The system must provide for trending and include
corrective and preventive action. Product recovery will be in keeping with the agreed upon procedure and documented. For Product to be considered releasable, all predetermined Specifications and other quality criteria must be met. 

  
 20 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	12.0	 SELF-INSPECTION 

Thorne will maintain a written program of self-inspection by technical personnel for all cGMP areas, as follows: 

 

	 	(a)	 Inspections will be conducted at least annually in keeping with a schedule. Thorne will provide documentation
of such inspections to BioTE upon BioTE’s written request. 

  

	 	(b)	 The persons performing the inspection should be knowledgeable in their respective fields and familiar with
cGMP. 

  

	 	(c)	 A report must be made of the observations. 

 

	 	(d)	 Management must evaluate the observations and corrective action. 

 

	 	(e)	 If applicable, an agreed upon corrective action must be initiated and tracked. 

 

	 	(f)	 A record of the observations and corrective actions will be maintained by Thorne, a copy of which will be
forwarded to BioTE upon request. 

  

	13.0	 STABILITY TESTING AND BEST-USED-BY DATING 

Thorne and BioTE will mutually agree on procedures for determining Best-Use-By
Dating for purchased BioTE products. Thorne will provide BioTE with a written explanation of the data to be used for determining Best-Use-By dates for each item. For all
private-label products where full stability testing has been performed on the finished product, Thorne will provide BioTE with a copy of the final summary report upon request. BioTE may contract with Thorne additional stability testing of finished
Products at BioTE’s expense. That stability testing program will be in writing and include the following elements: 
  

	 	(a)	 Product specific stability protocols that detail sample size, analytical/test methods including known and
unknown impurity profiles and limits, (if applicable), test intervals, storage condition(s), packaging components/configurations and reason for the study 

  

	 	(b)	 Stability-indicating test methods 

 

	 	(c)	 Criteria for batch selection for the program 

 

	 	(d)	 Secure, alarmed, and qualified storage 

 

	 	(e)	 Manual and/or electronic data collection 

 

	 	(f)	 Statistical analysis capability 

  
 21 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	 	(g)	 Out-of-specification
investigation and notification mechanism 

  

	 	(h)	 Data summarization and distribution 

Thorne will follow its SOP-00212 “Stability Testing Program.” 

 

	14.0	 STORAGE AND SHIPPING CONDITIONS 

Thorne will store manufactured Products in defined areas under appropriate conditions of temperature, humidity, and light and in accordance with
specifications such that quality is not affected. In addition, Thorne will have written procedures that describe storage, handling and distribution of the Product and minimally address: 

 

	 	(a)	 Periodic verification of actual storage conditions at Thorne’s facility. 

 

	 	(b)	 Storage of semi-finished or finished Product under controlled labeled conditions. 

 

	 	(c)	 Handling of Product that has been subjected to improper storage conditions. 

 

	 	(d)	 Selection and preparation of Product for shipment. 

 

	 	(e)	 Monitoring to ensure shipping conditions have been maintained where requirements exist. 

 

	15.0	 SUBCONTRACTING 

In the event that a Purchase Order authorizes Thorne the right to subcontract Product manufactured, tested, or processed, such contractor must meet cGMP
standards and BioTE’s regulatory requirements. Thorne must ensure that the subcontractor’s personnel are adequately educated and routinely trained according to cGMP regulations and job functions, in accordance with Section 2.6 above.
Thorne must notify BioTE which aspects of manufacturing will be subcontracted and what manufacturing facilities will be used when initial product manufacturing quotes are provided. BioTE agrees this information will be kept confidential and will
only be used for meeting cGMP compliance obligations. Thorne will provide results of audits of subcontracted manufacturing facilities to BioTE on request. 
  

	16.0	 AMENDMENTS 

This Agreement may only be modified by a writing signed by duly authorized representatives of Thorne and BioTE. The failure of either party to insist on
strict performance of any provision of this Agreement, or to exercise any right or remedy, will not be deemed a waiver of such performance, right or remedy, of that or any other provision of this Agreement. 

  
 22 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

	17.0	 ADDITIONAL TERMS AND CONDITIONS 

If this paragraph is initialed by Thorne and BioTE, then this Agreement is supplemented by the additional terms and conditions contained in the attached
Exhibit 1 (    ), ( ). 
  

	18.0	 FACSIMILIE SIGNATURE 

The Parties agree that a facsimile signature will be deemed an original. 

IN WITNESS WHEREOF, the parties have duly executed this Quality Agreement as of the date first written above and is effective until termination of the
Vendor Agreement between Thorne and BioTE. 
  

	
	FOR BIOTE MEDICAL, LLC
	
	/s/ Terry Weber
	Name: Terry Weber
	Title: Chief Executive Officer

  

	
	FOR THORNE RESEARCH, INC.
	
	/s/ Paul F. Jacobson
	Name: Paul F. Jacobson
	Title: Chief Executive Officer

  
 23 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 4 

Products and Specifications to be included on Certificate of Analysis 
  

													
	 Product
	  	 Description
	  	 Label Claim
	  	 Exp
Date
	  	 Test
Results
	  	 Test
Method
Reference
	  	 Signature
and Date

	ADK5	  	Capsule/Off-White	  	 Vitamin A (as Retinyl Palmitate) 1.5mg
  

Vitamin D (as D3) 5,000 IU
  

125mcg
  

Vitamin K (as MK04 and MK07)
  

500mcg
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:
							
	ADK10	  	Capsule/Off- White	  	 Vitamin A (as Retinyl Palmitate) 1.5mg
  

Vitamin D (as Vitamin D3) 10,000 IU
  

250mcg
  

Vitamin K (as MK-4 and MK-7)

 
 500mcg
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:

  
 24 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

													
	Iodine Plus	  	Capsule/Off-White	  	 Iodine (as Potassium Iodide)
  

12.5mg
  

Zinc (as Zinc Amino Acid Chelate)
  

10mg
  

Selenium (as L-Selenomethionine)
  

200mcg
	  	TBD	  	TBD	  	HPLC	  	Released for use by:
							
	DIM	  	Capsule/Light Brown	  	 Diindolylmethane (as Crystalline DIM
  

150mg
  

POM Pomegranate extract (whole fruit) (Punica granatum)
  

100mg
  

Sulforaphane Glucosinolate (from broccoli extract (seed) (Brassica oleracea italica))

 
 25mg
	  	24 months from date of production	  	TBD	  	HPLC	  	Released for use by:

  
 25 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

													
	Omega 3+ CoQ10	  	Gelcap/Orange	  	 EPA (Eicosapentaenoic Acid) (from Fish Oil)
  

450mg
  

DHA (Docosahexaenoic Acid) (from Fish Oil)
  

180mg
  

Coenzyme Q10
  

30mg
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:
							
	Methyl Factors Plus	  	Capsule/Light Orang	  	 Riboflavin (as Riboflavin 5’- Phosphate Sodium)
  

90mg
  

Vitamin 6 (as Pyridoxal 5’-Phosphate)
  

45mg
  

Vitamin B12 (as Methylcobalamin)
  

3mg
  

Betain Anhydrous (Trimethylglycine)
  

1.8 g
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:
							
	Curcumin SF	  	Capsule/Orange	  	 Curcumin Phytosome (Curcuma longa extract (root)/Phospholipid complex from Sunflower)

 
 1g
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:

  
 26 

 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

													
	Multi Strain Probiotic 208	  	Capsule/White	  	 HOWARU* Restore II Blend
  

20 Billion CFUs
  

•  Bifidobacterium lactis (Bi-07) 5 Billion CFUs

 
 •  Lactobacillus acidphilus
(NCFM) 5 Billion CFUs
  

•  Bifidobacterium lactis (bi-04) 5 Billion CFUs

 
 •  Lactobacillus paracasei (Lpc-37) 5 Billiob CFUs
	  	Per exp date printed on carton	  	TBD	  	HPLC	  	Released for use by:
							
	Bacillus Coagulans Probiotic	  	Capsule/White	  	 Bacillus Coagulans
  

133mg
  

2 Billion CFUs
	  	TBD	  	TBD	  	HPLC	  	Released for use by:

  
 27EX-10.14

 Exhibit 10.14 

UNCOMMITTED AND REVOLVING CREDIT LINE AGREEMENT 

UNCOMMITTED AND REVOLVING CREDIT LINE AGREEMENT dated as of February 12, 2021 between SUMITOMO MITSUI BANKING CORPORATION, a Japanese
banking corporation, having its offices at 277 Park Avenue, New York, New York 10172 (the “BANK”), and THORNE HEALTHTECH, INC., a corporation organized under the laws of Delaware, having its offices at 620 Omni Industrial Boulevard,
Summerville, South Carolina 29486 (the “BORROWER”). The parties hereto hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 
 SECTION 1.01.
DEFINED TERMS. As used in this AGREEMENT, the following terms have the following meanings (terms defined in the singular to have the same meaning when used in the plural and vice versa): 

“AGREEMENT” means this UNCOMMITTED AND REVOLVING CREDIT LINE AGREEMENT, together with all exhibits and schedules hereto, as the same
may be supplemented, modified, amended, restated or replaced from time to time in the manner provided herein. 
 “APPLICABLE INTEREST
RATE” means, with respect to each LOAN, the interest rate per annum quoted by the BANK and agreed to by the BORROWER at the time of making such LOAN. 

“BENEFICIAL OWNERSHIP CERTIFICATION” means a certification regarding beneficial ownership as required by the BENEFICIAL OWNERSHIP
REGULATION. 
 “BENEFICIAL OWNERSHIP REGULATION” means 31 C.F.R. §1010.230, as amended, modified, or supplemented from time
to time. 
 “BUSINESS DAY” means any day other than a Saturday, Sunday, or other day on which commercial banks in New York, New
York are authorized or required by law to close. 
 “CHANGE OF CONTROL” shall mean (x) the sale or transfer of more than
fifty percent (50%) of the outstanding capital stock of the BORROWER in a single transaction or series of related transactions to PERSON who are not then stockholders of the BORROWER, (y) the issuance of shares of common stock, or securities
convertible into or exercisable for shares of common stock, constituting more than fifty percent (50%) of the outstanding capital stock of the BORROWER immediately after issuance, to PERSON who were not holders of common stock, on an as converted
basis, immediately prior to such issuance or (z) the sale, exclusive license or other disposition of all or substantially all of the consolidated assets of the BORROWER and its majority owned subsidiaries in a single transaction or series of
related transactions to PERSON who are not then stockholders of the BORROWER. 
 “CREDIT LINE” means a discretionary and
uncommitted line of credit that the BANK establishes for the BORROWER pursuant to SECTION 2.01 hereof up to the amount referred to therein but which may be terminated in whole or reduced in part pursuant to SECTION 2.02 hereof. This CREDIT LINE
shall not be construed as the commitment of the BANK to make any LOAN or extension of credit. 

 “DEFAULT” means any of the events specified in SECTION 7.01 hereof, whether or not
any requirement for the giving of notice, the lapse of time, or both, or any other condition, has been satisfied. 
 “DISBURSEMENT
DATE” means, in relation to a LOAN, the date on which such LOAN is advanced, as requested by the BORROWER and agreed to by the BANK in accordance with SECTION 2.03. 

“DOLLARS”, “U.S. DOLLARS”, “US$”, “USD”, or “$” means the lawful currency of the United
States of America. 
 “EVENT OF DEFAULT” means any of the events specified in SECTION 7.01. 

“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder. 

“GAAP” means generally accepted accounting principles in the United States of America set forth in the opinions and pronouncements
of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board, as in effect from time to time. 

“GOVERNMENTAL AUTHORITY” means any nation or government, any state or other political subdivision thereof, any central bank (or
similar monetary or regulatory authority) thereof, any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, and any corporation or other entity owned or controlled, through stock
or capital ownership or otherwise, by any of the foregoing. 
 “GUARANTOR” means each of Mitsui & Co., Ltd., a Japanese
corporation; and Kirin Holdings Company, Limited, a Japanese corporation. 
 “LAST DRAWDOWN DATE” means February 11, 2022.

 “LETTER OF GUARANTEE” means the letter of guarantee executed by each GUARANTOR and required to be delivered by the BORROWER to
the BANK pursuant to SECTION 3.01 hereof, together with all exhibits and schedules thereto, as the same may be supplemented, modified, amended, restated or replaced from time to time in the manner provided therein. 

“LIEN” means any mortgage, deed of trust, pledge, security interest, assignment, deposit arrangement, charge or encumbrance, lien
(statutory or other), or other preferential arrangement (including any conditional sale or other title retention agreement, any financing lease having substantially the same economic effect as any of the foregoing, or any agreement to give any
security interest). 
 “LOAN” has the meaning assigned to such term in SECTION 2.01. 

“LOAN DOCUMENTS” means this AGREEMENT, the NOTE, each LETTER OF GUARANTEE, and any other agreement, document, instrument, or
contract furnished to the BANK in connection with any of the foregoing documents or supporting, securing, or otherwise relating to the LOANS, in each case as amended, amended and restated, supplemented, or otherwise modified from time to time. 

 “MARGIN STOCK REGULATIONS” means Regulation T, U and/or X of the Board of
Governors of the Federal Reserve System and the rules promulgated thereunder, as the same may be supplemented, modified, amended, restated, or replaced from time to time, or any corresponding or succeeding provisions of applicable law. 

“MATERIAL ADVERSE CHANGE” means any material adverse change in (a) the business, results of operations, properties, assets,
liabilities, condition (financial or otherwise), or prospects of the BORROWER, or the BORROWER and its SUBSIDIARIES taken as one enterprise; (b) the legality, validity, binding effect, or enforceability of any LOAN DOCUMENT; (c) the
ability of the BORROWER to fully and timely perform its obligations under any LOAN DOCUMENT, as determined from the perspective of a reasonable person in the BANK’s position; or (d) the rights, remedies, and benefits available to, or
conferred upon, the BANK under any LOAN DOCUMENT. 
 “MATURITY DATE” means, in relation to a LOAN, the date on which such LOAN is
due and payable, as requested by the BORROWER and agreed to by the BANK in accordance with SECTION 2.03. 
 “NOTE” has the meaning
assigned to such term in SECTION 2.05. 
 “PERSON” means an individual, partnership, corporation (including a business trust),
joint stock company, estate, trust, limited liability company, unlimited liability company, unincorporated association, joint venture, or other entity or GOVERNMENTAL AUTHORITY. 

“PRIME RATE” means the rate of interest per annum established by the BANK’s New York Branch from time to time as its
prime rate or base rate; each change in the PRIME RATE shall be effective from and including the date such change is established as being effective. 

“PROPERTY” means all types of real or personal property, including without limitation, tangible, intangible, or mixed property. 

“SANCTIONS” has the meaning assigned to such term in SECTION 4.10(a). 

“SUBSIDIARY” means, with respect to any PERSON (the “parent”) at any date, any corporation, limited liability company,
partnership, association, or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date,
as well as any other corporation, limited liability company, partnership, association or other entity (a) of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power
or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held, or (b) that is, as of such date, otherwise controlled, by the parent or one or more subsidiaries of the parent
or by the parent and one or more subsidiaries of the parent. 

 ARTICLE II 

AMOUNT AND TERMS OF LOANS 
 SECTION
2.01. REVOLVING CREDIT. The BANK may, upon request from the BORROWER, in the BANK’s sole and absolute discretion upon the terms and subject to the conditions hereinafter set forth, make one or more loans (each, a “LOAN”) to the
BORROWER from time to time during the period commencing on the date of this AGREEMENT and ending on (and including) the LAST DRAWDOWN DATE in an aggregate principal amount not to exceed at any time outstanding TWENTY MILLION DOLLARS
(US$20,000,000.00), provided that such amount may be reduced pursuant to SECTION 2.02 hereof (the “CREDIT LINE”). Each LOAN shall have a MATURITY DATE that is not less than one (1) day and not more than twelve (12) months
after the DISBURSEMENT DATE, as requested by the BORROWER in accordance with SECTION 2.03 and agreed to by the BANK. Subject to the terms and conditions hereof, the BORROWER may borrow, repay in whole or in part, and reborrow on a revolving basis,
up to the amount of the CREDIT LINE. The availability of the CREDIT LINE hereunder shall not be construed as the commitment of the BANK to make any LOAN. 

SECTION 2.02. REDUCTION AND TERMINATION OF CREDIT LINE. The BANK shall have the unrestricted right in its sole and absolute discretion, upon notice to
the BORROWER, to immediately terminate in whole or reduce in part the unused portion of the CREDIT LINE. 
 SECTION 2.03. NOTICE AND MANNER OF
BORROWING. Not later than 2:00 p.m., New York time on the requested DISBURSEMENT DATE, the BORROWER shall give the BANK telephonic application for each LOAN under this AGREEMENT to the BANK’s JDAD Loan Services Department (or such other
contact as the BANK may inform the BORROWER from time to time), which may or may not be accepted by the BANK, specifying (i) the DISBURSEMENT DATE; (ii) the principal amount; and (iii) the MATURITY DATE. The BANK will send written
confirmation of the LOAN to the BORROWER at the fax number or email address listed in SECTION 8.06 hereof. The BORROWER will acknowledge the information shown in the confirmation by promptly returning it to the BANK’s New York Branch by fax at
(212) 224-4537. Not later than 4:00 p.m., New York time, on the DISBURSEMENT DATE of the LOAN and upon fulfillment of the applicable conditions set forth in ARTICLE III hereof, the BANK will, subject to its
sole and absolute discretion and subject to the provisions of SECTION 2.01 hereof, make the LOAN available to the BORROWER in immediately available funds by crediting the amount thereof to the BORROWER’s account with the BANK, or to such other
account as the BORROWER shall inform the BANK in writing. All notices given under this SECTION 2.03 shall be irrevocable. The failure to give any confirmation referred to herein shall not release or diminish any of the BORROWER’s obligations
hereunder. 
 SECTION 2.04. REPAYMENT OF PRINCIPAL: PAYMENT OF INTEREST. 

(a) The entire principal amount of each LOAN shall be paid in immediately available funds on the MATURITY DATE for such LOAN. 

(b) Each LOAN will bear interest on the outstanding principal amount thereof at a rate per annum equal to the APPLICABLE INTEREST RATE.

 (c) Accrued interest on each LOAN will be payable in arrears on the MATURITY DATE for such
LOAN; provided that (i) interest accrued pursuant to SECTION 2.04(d) will be payable on demand, and (ii) in the event of any repayment or prepayment of any LOAN, accrued interest on the principal amount repaid or prepaid will be
payable on the date of such repayment or prepayment. 
 (d) If any EVENT OF DEFAULT under SECTION 7.01(1) or 7.01(2) hereof has occurred and
is continuing then, until such defaulted amount has been paid in full, to the extent permitted by law, such defaulted amounts will bear interest (after as well as before judgment), payable on demand, at a rate per annum equal to the PRIME
RATE plus 2%. 
 (e) All interest hereunder will be computed on the basis of a year of 360 days and will be payable for the actual
number of days elapsed (including the first day, but excluding the last day). 
 SECTION 2.05. NOTE. As additional evidence of the BORROWER’s
payment obligations hereunder, the BORROWER shall execute and deliver to the BANK pursuant to SECTION 3.01(1) a single grid promissory note (the “NOTE”), substantially in the form of EXHIBIT A attached hereto, setting forth the
CREDIT LINE as the maximum principal amount thereof and dated as of the date of this AGREEMENT, and made payable to the BANK. The BORROWER hereby authorizes the BANK to record on a schedule attached to the NOTE (or any similar form designated by the
BANK in its sole and absolute discretion from time to time, which may be maintained in its internal records and shown on a computer printout) the principal amount, APPLICABLE INTEREST RATE, MATURITY DATE, and other terms relevant to each LOAN, and
any such recordation shall be prima facie evidence of the accuracy of the information so recorded; provided that the BANK’S failure so to record shall not limit or otherwise affect the obligations of the BORROWER hereunder and
under the NOTE to repay the principal of and interest on the LOANS. 
 SECTION 2.06. FUNDING LOSS, INDEMNIFICATION; CAPITAL ADEQUACY AND OTHER CHARGES
AND COSTS. 
 (a) The BORROWER hereby agrees to indemnify and hold the BANK free and harmless from all losses, costs, and expenses that
the BANK may incur, to the extent not mitigated by the redeployment of deposits or other funds, as a result of (i) a default by the BORROWER in payment when due of the principal of or interest on a LOAN, (ii) the BORROWER’s failure
(other than due solely to a failure attributable to a default by the BANK) to make a borrowing or continuation with respect to a LOAN after making a request therefor, (iii) a prepayment (whether mandatory or otherwise, including but not limited
to, acceleration pursuant to ARTICLE VII hereof) of a LOAN before a scheduled payment date for interest or principal, or (iv) any DEFAULT or EVENT OF DEFAULT by the BORROWER under this AGREEMENT or any demand by the BANK for payment of any LOAN
permitted hereunder or under the NOTE. 
 (b) If the BANK determines at any time that any applicable law or governmental rule, regulation,
guideline, or order concerning capital adequacy, reserves, or similar requirements, or any change in interpretation or administration thereof by any GOVERNMENTAL AUTHORITY will have the effect of increasing the cost to the BANK or the amount of
capital required or expected to be maintained by the BANK as a result of the 

 
making or continuance of the LOANS, then the BORROWER agrees to pay to the BANK, upon its written demand therefor, such additional amounts as shall be required to compensate the BANK for such
increased costs. The BANK, upon determining that any additional amounts will be payable to the BANK pursuant to this paragraph, will give prompt written notice thereof to the BORROWER, which notice shall show in reasonable detail the basis for
calculation of such additional amounts, although the failure to give any such notice shall not release or diminish the obligations of the BORROWER to pay additional amounts pursuant to this paragraph. 

(c) If any present or future applicable law, rule, or regulation or any change therein or in the interpretation or administration thereof by
any GOVERNMENTAL AUTHORITY charged with the interpretation or administration thereof, or compliance by the BANK with any request or directive of any such GOVERNMENTAL AUTHORITY, whether or not having the force of law, results in an increase of the
cost to the BANK of making, renewing, or maintaining any LOAN, or reduces the amount of any sum receivable by the BANK under any LOAN, in the reasonable judgment of the BANK, then, upon demand by the BANK, the BORROWER agrees to pay to the BANK such
additional amount or amounts as would compensate the BANK for such increased cost or reduction. The BANK’s computation of such amount or amounts shall be binding on the BORROWER absent manifest error. 

SECTION 2.07. METHOD OF PAYMENT. The BORROWER shall make each payment of principal of and interest on the LOANS, in lawful money of the United States
in immediately available funds, not later than 3:00 p.m. (New York time) on the date when such payment is due, via Fedwire or CHIPS to the account described below, or to such other location or in such other manner as the BANK may notify the BORROWER
in writing: 
  

			
	 Bank Name:
	  	Sumitomo Mitsui Banking Corp., New York
	 SWIFT:
	  	SMBCUS33
	 ABA Number:
	  	0260-0967-4
	 Account Name:
	  	SMBC Loan Operations New York
	 Account Number:
	  	423001
	 Reference:
	  	Thorne HealthTech, Inc.
	 Attn:
	  	BCDAD JDAD Loan Services

 The BORROWER hereby authorizes the BANK to charge any amounts due hereunder or under the NOTE from time to time against the
BORROWER’s account #351905 or any other account of the BORROWER with the BANK. The BORROWER may, with the BANK’s prior consent, and on not less than five days’ notice, prepay the principal and interest of any LOAN in whole or
in part, but only on condition that the prepayment is accompanied by payment of any and all additional costs, as determined by the BANK, that the BANK may incur as a result of such prepayment, including, without limitation, the breaking of any
deposit, the redeployment of funds released by any prepayment, the termination of any swap or hedging contract, or otherwise. 
 SECTION 2.08. PAYMENTS
ON NON-BUSINESS DAYS. Whenever payment shall fall due on a day which is not a BUSINESS DAY, payment shall be made on the next succeeding BUSINESS DAY, unless such BUSINESS DAY falls in the following
calendar month, in which case payment shall be due on the next preceding BUSINESS DAY. 

 ARTICLE III 

CONDITIONS PRECEDENT 
 SECTION 3.01.
CONDITIONS PRECEDENT TO INITIAL AND ALL LOANS. The BANK may in its sole and absolute discretion make LOANS available to the BORROWER, subject to the BANK’s receipt of the following, each of which shall be in form and substance
satisfactory to the BANK: 
 (1) AGREEMENT AND NOTE. This AGREEMENT and the NOTE, each duly executed by the BORROWER. 

(2) EVIDENCE OF ALL CORPORATE ACTION BY THE BORROWER. Certified copies of the unanimous written consent of the Board of Directors of
the BORROWER or a certified copy of the resolutions duly adopted by the Board of Directors authorizing the execution, delivery, and performance of this AGREEMENT, the NOTE, and any other documents to be delivered pursuant to this AGREEMENT. 

(3) INCUMBENCY AND SIGNATURE CERTIFICATE OF THE BORROWER. A certificate of the President or Vice President (or other appropriate
officer) of the BORROWER certifying the names and true signatures of the officers of the BORROWER authorized, pursuant to the Board of Directors’ resolutions referred to in paragraph (2) above, to sign this AGREEMENT, the NOTE, and any
other documents to be delivered by the BORROWER pursuant to this AGREEMENT. 
 (4) BENEFICIAL OWNERSHIP CERTIFICATION. At least five
days prior to the first DISBURSEMENT DATE, a BENEFICIAL OWNERSHIP CERTIFICATION in relation to the BORROWER. 
 (5) LETTERS OF
GUARANTEE. The LETTER OF GUARANTEE duly executed by each GUARANTOR. 
 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES 

The BORROWER hereby represents and warrants to the BANK as follows at each time it makes an application for a LOAN: 

SECTION 4.01. DUE INCORPORATION; GOOD STANDING. The BORROWER is a corporation, duly organized and validly existing under the laws of the jurisdiction of
its incorporation, and is properly licensed and in good standing in, and where necessary to maintain the BORROWER’s rights and privileges, has complied with the fictitious name statute of, every jurisdiction in which the BORROWER is doing
business. 
 SECTION 4.02. CORPORATE POWER; AUTHORIZATION. The execution and delivery of this AGREEMENT, the NOTE, and each other LOAN DOCUMENT to
which it is a party and the performance of its obligations hereunder and thereunder are within the BORROWER’s corporate powers, have been duly authorized, and will not contravene or conflict with its charter or bylaws (or such other
organizational and governing documents as may be applicable) or any agreement, instrument, or document to which the BORROWER is a party or by which the BORROWER or any of its PROPERTY is bound or affected. 

 SECTION 4.03. GOVERNMENT ACTION. No approval, consent, exemption, or other action by, or notice to or
filing with, any GOVERNMENTAL AUTHORITY is necessary in connection with the execution, delivery, performance, or enforcement of this AGREEMENT, the NOTE, or any other LOAN DOCUMENT, except as may have been obtained and certified copies of which have
been delivered to BANK. 
 SECTION 4.04. NO LEGAL BAR. There is no law, rule, or regulation, nor is there any judgment, decree, or order of any court
or GOVERNMENTAL AUTHORITY binding on the BORROWER that would be contravened by the execution, delivery, performance, or enforcement of this AGREEMENT, the NOTE, or any other LOAN DOCUMENT. 

SECTION 4.05. ENFORCEABLE OBLIGATION. This AGREEMENT is a legal, valid, and binding agreement of the BORROWER, enforceable against the BORROWER in
accordance with its terms, and the NOTE and each other LOAN DOCUMENT to which the BORROWER is a party, when executed and delivered (and as endorsed from time to time), will be similarly legal, valid, binding, and enforceable. 

SECTION 4.06. LITIGATION. Except as previously disclosed to the BANK in writing, there are no legal actions or other proceedings pending or, to the
best of the BORROWER’s knowledge, threatened against the BORROWER which, individually or in the aggregate, could reasonably be expected to result in a MATERIAL ADVERSE CHANGE. There are no outstanding and unsatisfied final judgments or decrees
against the BORROWER for money damages, fines, or penalties which, individually or in the aggregate, could result in a MATERIAL ADVERSE CHANGE. 
 SECTION
4.07. NO DEFAULT. No event has occurred and is continuing or would result from the incurring of obligations by the BORROWER under this AGREEMENT, the NOTE, or any other LOAN DOCUMENT that is a default under any agreement or document to which
the BORROWER is a party or which, with the passing of time or giving of notice or both, would become a default under any such document. 
 SECTION 4.08.
NO CONFLICTING AGREEMENTS. Except as disclosed in writing by the BORROWER to the BANK prior to the date hereof, the BORROWER is not in default under any agreement to which it is a party or by which it or any of its PROPERTY is bound, the
effect of which, individually or in the aggregate, could reasonably be expected to result in a MATERIAL ADVERSE CHANGE. 
 SECTION 4.09. TAXES. The
BORROWER has filed or caused to be filed all tax returns required to be filed, and has paid, or has made adequate provision for the payment of, all taxes shown to be due and payable on said returns or in any assessments made against it, and no tax
liens have been filed and no claims are being asserted with respect to such taxes that are required to be reflected in the financial statements of the BORROWER and are not so reflected therein. 

 SECTION 4.10. COMPLIANCE WITH LAW. 

(a) None of the BORROWER, any of its SUBSIDIARIES or, to the knowledge of the BORROWER, any director, officer, employee, or agent of the
BORROWER or any of its SUBSIDIARIES is a PERSON that is, or is owned or controlled by PERSONS that are: (i) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury’s Office of Foreign Assets Control
(OFAC), the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury, the Japanese government, including those imposed under the Foreign Exchange Act and the Import Trade Control Order of Japan
(Cabinet Order No. 414 of 1949, as amended), or other relevant sanctions authority (collectively, “SANCTIONS”), or (ii) located, organized, or resident in a country or territory that is the subject of SANCTIONS, including
Crimea, Cuba, Iran, North Korea, and Syria, except as previously disclosed to the BANK. 
 (b) The BORROWER, its SUBSIDIARIES, and their
respective directors, officers, employees, and agents are in compliance with (i) all applicable SANCTIONS and (ii) the FCPA and all other applicable anti-corruption laws. 

(c) The BORROWER and its SUBSIDIARIES have instituted and maintain policies and procedures designed to ensure compliance with
(i) applicable SANCTIONS and (ii) the FCPA and all other applicable anti-corruption laws. 
 SECTION 4.11. NO MISREPRESENTATION. Neither
this AGREEMENT, nor any other LOAN DOCUMENT, nor any certificate, notice, report, financial statement, or document furnished to date or to be furnished by the BORROWER in connection with the transactions contemplated hereby contains or will contain
a misrepresentation or misstatement of material fact, or omits or will omit to state a material fact required to be stated in order to make the statements herein or therein contained (taken as a whole) not misleading in the light of the
circumstances under which made. 
 SECTION 4.12. RANKING OF LOAN; LIENS. The payment obligations of the BORROWER under this AGREEMENT and the NOTE
are and will at all times be unsubordinated general obligations of the BORROWER, and rank and will at all times rank at least pari passu with all other present and future unsubordinated unsecured indebtedness of the BORROWER. 

ARTICLE V 

AFFIRMATIVE COVENANTS 

So long as any indebtedness or obligation remains unpaid or outstanding hereunder, the BORROWER will: 

SECTION 5.01. FINANCIAL AND OTHER INFORMATION. Deliver to the BANK such information respecting the business, properties, assets, liabilities, condition
(financial or otherwise), operations, or prospects of the BORROWER as the BANK may from time to time reasonably request, including: 
 (a) as
soon as available and in any event within 120 days after the end of each fiscal year of the BORROWER, its consolidated audited annual financial statements, which shall include at least its balance sheet and related statements of operations,
stockholders’ equity and cash flow as of the end of and for such year, setting forth in comparative form the figures for the previous fiscal year, all reported on by independent public accountants of recognized national standing to the effect
that such financial statements present fairly in all material respects the financial condition and results of operations of the BORROWER and its consolidated subsidiaries on a consolidated basis in accordance with GAAP consistently applied; 

 (b) if available, as soon as available and in any event within 90 days after the end of the
first semiannual reporting period of each fiscal year of the BORROWER, its consolidated semiannual financial statements, which shall include at least its balance sheet and related statements of operations, stockholders’ equity and cash flow as
of the end of and for such period setting forth in comparative form the figures for the corresponding period of the previous fiscal year, presenting fairly in all material respects the financial condition and results of operations of the BORROWER
and its consolidated subsidiaries on a consolidated basis in accordance with GAAP consistently applied (except as differences from GAAP shall have been disclosed to, and approved by, the BANK), subject to normal
year-end adjustments and the absence of footnotes; and 
 (c) concurrently with any delivery of
financial statements under clause (a) above, a certificate of a responsible financial officer of the BORROWER, in the form of EXHIBIT B attached hereto, certifying to such officer’s knowledge whether a DEFAULT or EVENT OF DEFAULT
has occurred and, if a DEFAULT or EVENT OF DEFAULT has occurred, specifying the details thereof and any action taken or proposed to be taken with respect thereto. 

SECTION 5.02. NOTICE. Promptly notify the BANK in writing of: 

(1) all litigation affecting the BORROWER as a defendant where the amount claimed in a single litigation action is in excess of $100,000 or
when the aggregate amount claimed in all litigation actions is in excess of $500,000; 
 (2) any substantial dispute between the BORROWER
and any GOVERNMENTAL AUTHORITY; 
 (3) any DEFAULT or EVENT OF DEFAULT; and 

(4) any other matters which, individually or in the aggregate, have resulted or could reasonably be expected to result in a MATERIAL ADVERSE
CHANGE. 
 SECTION 5.03. PAYMENT OF OBLIGATIONS. Pay all obligations, including taxes, when due, except such as may be contested in good faith by
appropriate proceedings and for which the BORROWER has established reserves on its books which are reasonable and adequate. 
 SECTION 5.04. COMPLIANCE
WITH LEGAL REQUIREMENTS. 
 (a) Maintain in effect policies and procedures designed to ensure compliance by the BORROWER, its
SUBSIDIARIES, and their respective directors, officers, employees, and agents with (i) applicable SANCTIONS and (ii) the FCPA and any other applicable anti-corruption laws. 

(b) At all times comply with all laws, rules, regulations, orders, and directions of any GOVERNMENTAL AUTHORITY having jurisdiction over it or
its business. 

 SECTION 5.05. MAINTAIN EXISTENCE; PROPERTY. Maintain and preserve (i) its existence as a legal
entity and all rights, privileges and franchises now enjoyed; and (ii) all of its PROPERTIES that are used or useful in the conduct of its business in good working order and condition, ordinary wear and tear excepted. 

SECTION 5.06. BOOKS AND RECORDS. Maintain adequate books, accounts, and records, all in accordance with GAAP, and permit employees or agents of BANK,
at any reasonable time and as often as may reasonably be desired, to inspect its PROPERTIES, and to examine or audit its books, accounts, and records and make copies thereof and to discuss the business, operations, PROPERTIES, and financial and
other conditions of the BORROWER with officers of the BORROWER. 
 SECTION 5.07. INSURANCE. To the extent there exists any real property security
interest, maintain and keep in force, on all of its property such insurance as is normal for the industry in which the BORROWER conducts its business and is satisfactory to BANK as to amount, nature, and carrier, covering fire damage (including use
and occupancy), public liability, product liability, property damage, and workers’ compensation, and deliver to BANK upon request a schedule certified to be correct by a responsible officer of the BORROWER setting forth all insurance in force
as of the date of such schedule. 
 SECTION 5.08. FURTHER ASSURANCES. The BORROWER will from time to time perform any and all acts and execute any
and all additional documents as may be reasonably requested by BANK to give effect to the purposes of this AGREEMENT, the NOTE, and the other LOAN DOCUMENTS, if any. 

ARTICLE VI 
 NEGATIVE
COVENANTS 
 So long as any indebtedness or obligation remains unpaid or outstanding hereunder, the BORROWER hereby agrees as
follows: 
 SECTION 6.01. LIMITATIONS ON FUNDAMENTAL CHANGES. The BORROWER will not merge into or consolidate with any other PERSON, or permit any
other PERSON to merge into or consolidate with it, or sell, transfer, lease or otherwise dispose of (in one transaction or in a series of transactions) all or substantially all of its assets (in each case, whether now owned or hereafter acquired),
or liquidate or dissolve. 
 SECTION 6.02. USE OF PROCEEDS. 

(a) No part of the proceeds of any LOAN will be used to buy or carry, or to extend credit to any other PERSON to buy or carry, any
“margin stock” (as defined in Regulation U of the Board of Governors of the United States Federal Reserve System) in violation of MARGIN STOCK REGULATIONS. 

(b) The BORROWER will not request any LOAN, and the BORROWER shall not use, and the BORROWER will procure that its SUBSIDIARIES and its or
their respective directors, officers, employees and agents will not use, the proceeds of any LOAN (i) to fund any activities or business of or with any PERSON, or in any country or territory, that, at the time of such funding, is the subject of
SANCTIONS, or (ii) in any other manner that would result in a violation of SANCTIONS applicable to any party hereto. 

 (c) No part of the proceeds of the LOANS will be used, directly or indirectly, in
furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any PERSON in violation of the FCPA or any other applicable anti-corruption law. 

SECTION 6.03. NEGATIVE PLEDGE. The BORROWER will not create, incur, assume, or suffer to exist any LIEN upon or with respect to any of its PROPERTY,
whether now owned or hereafter acquired, other than: 
 (a) LIENS imposed by any GOVERNMENTAL AUTHORITY for taxes, assessments, or charges
not yet due or which are being contested in good faith and by appropriate proceedings if adequate reserves with respect thereto are maintained on the books of the BORROWER in accordance with GAAP; and 

(b) easements, rights-of-way, restrictions, and other similar
encumbrances incurred in the ordinary course of business and encumbrances consisting of zoning restrictions, easements, licenses, restrictions on the use of property, or minor imperfections in title thereto which, in the aggregate, are not material
in amount, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of the BORROWER. 

ARTICLE VII 
 EVENTS
OF DEFAULT 
 SECTION 7.01. EVENTS OF DEFAULT. The occurrence of any of the following events will constitute an EVENT OF DEFAULT under this
AGREEMENT and the NOTE: 
 (1) The BORROWER fails to pay any principal of any LOAN when and as the same becomes due and payable, whether at
the due date thereof or at a date fixed for prepayment thereof or otherwise. 
 (2) The BORROWER fails to pay any interest on any LOAN or
any fee or any other amount (other than an amount referred to in SECTION 7.01(1)) payable under this AGREEMENT or any other LOAN DOCUMENT when and as the same shall become due and payable, and such failure continues unremedied for a period of ten
(10) days. 
 (3) Any representation or warranty made or deemed made by or on behalf of the BORROWER in or in connection with this
AGREEMENT or any of the other LOAN DOCUMENTS, or in any amendment hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this AGREEMENT or any other LOAN DOCUMENT or any
amendment hereof or thereof, proves to have been false or misleading in any material respect when made or deemed made. 
 (4) The BORROWER
(i) fails to pay its debts generally as they come due, (ii) conceals, removes, or transfers any of its PROPERTY in violation or evasion of any bankruptcy, fraudulent conveyance, or similar law, (iii) makes a general assignment for the
benefit of its creditors, (iv) applies for or consents to the appointment of a receiver, trustee, assignee, custodian, sequestrator, liquidator, or similar official for itself or any of its PROPERTY, (v) files any petition or action for
relief under any bankruptcy, reorganization, insolvency, or moratorium law, or any other law or laws for the relief of, or relating to, debtors, (vi) is adjudicated a bankrupt or insolvent or (vii) takes any action for the purpose of effecting
any of the foregoing. 

 (5) An involuntary petition is filed under any bankruptcy, reorganization, insolvency,
moratorium, or similar statute against the BORROWER or a custodian, receiver, trustee, or assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody, or control of any PROPERTY of the BORROWER unless
such petition or appointment is set aside or withdrawn or ceases to be in effect within 30 days from the date of said filing or appointment. 

(6) One or more judgments for the payment of money in an aggregate amount in excess of $250,000 shall be rendered against the BORROWER (or any
combination thereof), and the same shall remain undischarged for a period of ten (10) consecutive days during which execution is not effectively stayed, or any action is legally taken by a judgment creditor to attach or levy upon any assets of
the BORROWER to enforce any such judgment. 
 (7) All, or such as in the opinion of BANK constitutes substantially all, of the PROPERTIES of
the BORROWER is condemned, seized, or appropriated. 
 (8) The BORROWER fails to observe or perform any covenant, condition, or agreement
contained in (i) SECTION 5.02(3), SECTION 5.05(i), SECTION 5.04(a), or ARTICLE VI; or (ii) any other provision of this AGREEMENT or the NOTE (and not described in SECTIONS 7.01(1) or (2)) and such failure is not remediable or, if
remediable, continues unremedied for a period of 30 days after the earlier of (x) the date the BORROWER becomes aware thereof or (y) the date the BANK gives notice to the BORROWER with respect thereto. 

(9) The BORROWER is in breach of or default under any term, condition, provision or covenant contained in any agreement to which it is a party
relating to borrowed money. 
 (10) Any LETTER OF GUARANTEE or any other document issued in support of the obligations of the BORROWER to
the BANK, or any replacement of any of the foregoing, expires without renewal, is disclaimed or disavowed, or, in the case of a guarantee, ceases to be the valid, binding and enforceable obligation of the guarantor thereunder, or the issuer fails to
observe or perform any covenant, undertaking, or other obligation thereunder. 
 (11) A CHANGE OF CONTROL occurs. 

(12) Any one or more events occur or conditions exist that, individually or in the aggregate, have resulted in or could reasonably be expected
to result in a MATERIAL ADVERSE CHANGE. 
 SECTION 7.02. REMEDIES. Upon the occurrence of any EVENT OF DEFAULT (other than an event described in
SECTION 7.01(4) or 7.01(5)), the BANK may, by notice to the BORROWER, declare the LOANS then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be
due and payable), and thereupon the principal of the LOANS so declared to be due and payable, together with accrued interest thereon and all fees and other obligations of the BORROWER accrued hereunder, will become due and payable immediately,
without presentment, demand, protest or other notice of any kind, all of which are hereby waived by 

 
the BORROWER; and in case of any event described in SECTION 7.01(4) or 7.01(5), the principal of the LOANS then outstanding, together with accrued interest thereon and all fees and other
obligations of the BORROWER accrued hereunder, will automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the BORROWER. The foregoing remedies are in addition to any
and all other remedies available to BANK under this AGREEMENT, the NOTE, or any other LOAN DOCUMENT, at law, or in equity. The BORROWER hereby agrees to indemnify the BANK and save the BANK harmless from and against any and all costs, losses, or
expenses incurred by the BANK as a result of the occurrence of an EVENT OF DEFAULT or the repayment of any amount hereunder or under the NOTE other than on the date or dates originally due (including without limitation such as are incurred in
connection with the reemployment or liquidation of funds acquired from third parties (including affiliates) by the BANK in order to maintain any amount theretofore outstanding hereunder or under the NOTE, the termination of any hedging contract or
swap or other arrangement relating to the funding of the LOANS). 
 ARTICLE VIII 

MISCELLANEOUS 
 SECTION 8.01.
INDEMNITY. The BORROWER hereby agrees to indemnify, defend, reimburse, and hold harmless BANK and each of its affiliates, and all the directors, officers, employees, agents, legal counsel, and advisors of BANK (each, an “INDEMNIFIED
PARTY”) from and against all claims, actions, proceedings, suits, damages, losses, liabilities, costs, and expenses, including the fees and out-of-pocket expenses
of counsel that may be incurred by or asserted against any INDEMNIFIED PARTY in connection with, or arising out of, or relating to any transaction or proposed transaction (whether or not consummated), contemplated by this AGREEMENT or any LOAN
DOCUMENT. 
 SECTION 8.02. SUCCESSORS AND ASSIGNS; ASSIGNMENTS; PARTICIPATIONS. The provisions of this AGREEMENT shall be binding upon and inure to
the benefit of the parties hereto and their respective successors and assigns, except that the BORROWER may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the BANK. The BANK may at
any time sell, assign, transfer, or grant participations in all or any part of, or any interest in, BANK’s rights, benefits and obligations under any of the LOAN DOCUMENTS (including all or a portion of the LOANS or the CREDIT LINE). The BANK
may at any time pledge or assign a security interest in all or any portion of its rights under this AGREEMENT to secure obligations of the BANK, including any pledge or assignment to secure obligations to a Federal Reserve Bank. 

SECTION 8.03. ENTIRE AGREEMENT. This AGREEMENT and the LOAN DOCUMENTS integrate all the terms and conditions mentioned herein or incidental hereto, and
supersede all oral negotiations and prior writings with respect to the subject matter hereof. This AGREEMENT renews and extends, without novation, the Uncommitted and Revolving Credit Line Agreement dated February 14, 2020 between the BORROWER,
formerly known as Thorne Holding Corp., and the BANK, and the terms governing extensions of credit outstanding thereunder shall be amended to reflect the terms contained in this AGREEMENT upon the execution and delivery hereof. 

 SECTION 8.04. COUNTERPARTS This AGREEMENT and any amendments, waivers, consents, or supplements may
be executed in as many counterparts as may be deemed necessary or convenient, and by the different parties hereto on separate counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but
one and the same agreement. 
 SECTION 8.05. AMENDMENTS. ETC. No amendment, modification, termination, or waiver of any provision of any LOAN
DOCUMENT to which the BORROWER is a party, nor consent to any departure by the BORROWER from any such provision, shall in any event be effective unless the same shall be in writing and signed by the BANK, and then such amendment, modification,
termination, waiver, or consent shall be effective only in the specific instance and for the specific purpose for which it is given. 
 SECTION 8.06.
NOTICES, ETC. All notices and other communications provided for under this AGREEMENT shall be in writing, delivered in person, or sent by overnight courier, first class mail (postage prepaid), fax or email to: 

 

			
	If to the BORROWER: 	 	 Thorne HealthTech, Inc.
 620 Omni
Industrial Boulevard

		 	Summerville, South Carolina 29486
		 	Attention: Mr. Scott Wheeler
		 	                 Chief Financial Officer
		 	Telephone:     (843) 501-0286
		 	email:         swheeler@Thorne.com
		
	If to the BANK:	 	Sumitomo Mitsui Banking Corporation
		 	277 Park Avenue
		 	New York, New York 10172
		 	Attention:     JDAD
		 	Telephone:   (212) 224-4000
		 	Fax:               (212) 593-9514

 or at such other address as shall be designated by either party in a written notice to the other party complying as to
delivery with the terms of this SECTION 8.06. All such notices and communications shall be effective when deposited in the mails, faxed, or emailed, as applicable, except that notices to the BANK pursuant to the provisions of ARTICLE II hereof shall
be effective when received by the BANK. 
 SECTION 8.07. NO WAIVER; REMEDIES. No failure on the part of the BANK to exercise, and no delay in
exercising, any right, power or remedy under any LOAN DOCUMENT shall operate as waiver thereof; nor shall any single or partial exercise of any right under any LOAN DOCUMENT preclude any other or further exercise thereof or exercise of any other
right. The remedies provided in the LOAN DOCUMENTS are cumulative and not exclusive of any remedies provided by law. 
 SECTION 8.08. COSTS, EXPENSES,
AND TAXES. The BORROWER hereby agrees to pay on demand after giving borrowing written notice of the demand (i) all reasonable out-of-pocket expenses incurred by
the BANK and its affiliates, including the reasonable fees, charges, and disbursements of counsel for the BANK, in connection with the preparation, negotiation, execution, delivery, and administration of the LOAN DOCUMENTS and any

 
amendments, waivers, or other modifications of the provisions of any LOAN DOCUMENT (whether or not the transactions contemplated by the LOAN DOCUMENTS are consummated); and (ii) all out-of-pocket expenses incurred by the BANK, including the fees, charges, and disbursements of any counsel for the BANK, in connection with the enforcement or protection of
its rights (A) in connection with the LOAN DOCUMENTS, including its rights under this SECTION 8.08, or (B) in connection with the LOANS, including all such
out-of-pocket expenses incurred in connection with any restructuring, workout, or negotiations in respect of the LOAN DOCUMENTS or the LOANS. In addition, the BORROWER
shall pay any and all stamp and other taxes and fees payable or determined to be payable in connection with the execution, delivery, filing, and recording of any of the LOAN DOCUMENTS and the other documents to be delivered under any of the LOAN
DOCUMENTS, and agrees to save the BANK harmless from and against any and all liabilities with respect to or resulting from any delay in paying or omission to pay such taxes and fees. 

SECTION 8.09. DEDUCTIONS. All payments by the BORROWER to the BANK under this AGREEMENT or under the NOTE are to be made net and free of any and all
taxes (except for taxes based upon the overall net income of the BANK), duties, imposts, fees, withholdings, or deductions (the “DEDUCTIONS”) of any nature now or hereafter imposed. If any DEDUCTION is, by law, required to be made from any
payment hereunder, then the BORROWER shall pay to the BANK such additional amount as will result in receipt by the BANK of a net amount equal to the amount the BANK would have received hereunder had no such DEDUCTION been required. In such event the
BORROWER shall, as soon as practical, deliver to the BANK a receipt issued by the relevant taxing authority evidencing the amount of such DEDUCTION and its payment. If the BORROWER is required to pay an additional amount on account of any such
DEDUCTION, the BORROWER shall have the right, on not less than three BUSINESS DAYS’ prior written notice to the BANK, to repay the applicable LOAN. 

SECTION 8.10. RIGHT OF SET OFF. Upon the occurrence and during the continuance of any EVENT OF DEFAULT the BANK is hereby authorized at any time and
from time to time, without notice to the BORROWER (any such notice being expressly waived by the BORROWER to the fullest extent permitted by applicable law), to set off and apply any and all deposits (general or special, time or demand, provisional
or final) at any time held, and other indebtedness at any time owing by the BANK to or for the credit or the account of the BORROWER against any and all of the obligations of the BORROWER now or hereafter existing under the AGREEMENT or the NOTE or
any other LOAN DOCUMENT, irrespective of whether or not the BANK shall have made any demand under this AGREEMENT or such other LOAN DOCUMENT and although such obligations may be unmatured. The BANK agrees promptly to notify the BORROWER after any
such set off and application, provided that the failure to give such notice shall not affect the validity of such set off and application. The rights of the BANK under this SECTION 8.10 are in addition to other rights and remedies (including,
without limitation, other rights of set off) which the BANK may have. 
 SECTION 8.11. GOVERNING LAW; CONSENT TO JURISDICTION. This AGREEMENT and the
NOTE shall be governed by and construed in accordance with the laws of the State of New York. Any legal action or proceedings with respect to this AGREEMENT against the BORROWER may be brought in the courts of the United States of America or the
State of New York as the BANK may elect, and, by execution and delivery of this AGREEMENT, the BORROWER hereby (i) accepts for itself, generally and unconditionally, the non-exclusive

 
jurisdiction of the aforesaid courts, (ii) irrevocably agrees to be bound by any judgment of any such court with respect to this AGREEMENT or the NOTE, and (iii) irrevocably waives, to
the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of venue of any suit, action, or proceedings with respect to this AGREEMENT brought in any court of the United States of America or the State of New
York located in the City of New York, and further irrevocably waives any claim that any such suit, action, or proceeding brought in any such court has been brought in an inconvenient forum. In the case of the courts of the United States of America
and State of New York the BORROWER hereby agrees to receive service of process in any legal action or proceedings with respect to this AGREEMENT at its offices set forth in SECTION 8.06. Nothing herein shall affect the right to serve process in any
other manner permitted by the law. The BORROWER hereby agrees that the mailing of such process to the BORROWER shall be deemed personal service and accepted by the BORROWER for any legal action or proceedings with respect to this AGREEMENT. 

SECTION 8.12. SEVERABILITY OF PROVISIONS. Any provision of any LOAN DOCUMENT which is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of such LOAN DOCUMENT or affecting the validity or enforceability of such provision in any other jurisdiction. 

SECTION 8.13. HEADINGS. ARTICLE and SECTION headings in this AGREEMENT are for the convenience of reference only and shall not constitute a part of the
applicable LOAN DOCUMENTS for any other purpose. 
 SECTION 8.14. WAIVER OF JURY TRIAL. THE BANK AND THE BORROWER MUTUALLY WAIVE THE RIGHT TO TRIAL
BY JURY IN ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT. 
 SECTION 8.15. PATRIOT ACT. The BANK hereby notifies the BORROWER that
pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56) (the “ACT”), it is required to obtain, verify, and record information that identifies each borrower, guarantor, or
grantor (each, a “LOAN PARTY”), which information includes the name, and address of each LOAN PARTY and other information that will allow the BANK to identify such LOAN PARTY in accordance with the ACT. 

SECTION 8.16. CONFIDENTIALITY. The BANK agrees to keep confidential any information provided to it by or on behalf of the BORROWER pursuant to or in
connection with the LOAN DOCUMENTS, other than information that has been publicly disclosed or is otherwise publicly available other than in breach of this SECTION 8.16; provided that nothing herein shall prevent the BANK from disclosing any
such information: (i) to any potential assignee of or participant in the LOANS or any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the BORROWER and its obligations which agrees in
writing to comply with the provisions of this section; (ii) to its affiliates and the employees, officers, partners, directors, agents, attorneys, accountants, and other professional advisors of it and its affiliates, provided that such
recipients are obligated to keep the information confidential; (iii) upon the request or demand of any GOVERNMENTAL AUTHORITY having jurisdiction over the BANK, including during the course of periodic examinations and reviews of the BANK;
(iv) in connection with the exercise of any remedy hereunder; (v) in connection with any litigation to which the BANK may be a party; and (vi) if, prior to such information having been so provided or obtained, such information was
already in the BANK’s possession on a non-confidential basis without, to the best of the BANK’s knowledge, a duty of confidentiality to the BORROWER being violated. 

[signature page follows] 

 IN WITNESS WHEREOF, the parties hereto. have caused this AGREEMENT to be executed by their
respective officers thereunto duly authorized, as of the date first above written. 
  

			
	THORNE HEALTHTECH, INC.
		
	By:	 	/s/ Scott S. Wheeler
		 	Scott S. Wheeler
		 	Chief Financial Officer

  

			
	 SUMITOMO MITSUI BANKING CORPORATION

		
	By:	 	 /s/ Satoshi Takahara

		 	 Name: Satoshi Takahara

		 	 Title: Excutive Director

 EXHIBIT A 

[Form of] 
 UNCOMMITTED AND
REVOLVING CREDIT NOTE 
  

					
	 US$20,000,000.00
	  		  	February 12, 2021
	 (maximum amount)
	  		  	

 FOR VALUE RECEIVED, the undersigned THORNE HEALTHTECH, INC. (the “BORROWER”), HEREBY UNCONDITIONALLY
PROMISES TO PAY to the order of SUMITOMO MITSUI BANKING CORPORATION (the “BANK”), the principal sum of TWENTY MILLION DOLLARS (US$20,000,000.00) or, if less, the aggregate unpaid principal amount of all LOANS made to the BORROWER pursuant
to the LINE AGREEMENT referred to below, together with interest on the unpaid principal amount of each LOAN from time to time outstanding hereunder at the rates, and payable in the manner and on the dates, specified in the LINE AGREEMENT, the
provisions of which are incorporated by reference in this NOTE. 
 The BANK shall record the date and amount of each LOAN made, the
APPLICABLE INTEREST RATE, the amount of principal and interest due and payable from time to time hereunder, each payment thereof, and the resulting unpaid principal balance hereof, on the schedule attached to this NOTE or any similar form designated
by the BANK in its sole and absolute discretion from time to time, and any such recordation shall be prima facie evidence of the accuracy of the information so recorded; provided that the BANK’s failure so to record shall not
limit or otherwise affect the obligations of the BORROWER hereunder and under the LINE AGREEMENT to repay the principal of and interest on the LOANS. 

Both principal and interest are payable in the currency of the LOAN and in immediately available funds to the BANK at 277 Park Avenue, New
York, NY 10172, or at such other place as may be designated in writing by the holder of this NOTE. 
 This promissory note is the NOTE
referred to in, and is subject to and entitled to the benefits of, the UNCOMMITTED AND REVOLVING CREDIT LINE AGREEMENT dated as of February 12, 2021 between the BORROWER and the BANK (as amended, modified, renewed or extended from time to time,
the “LINE AGREEMENT”). Capitalized terms used herein shall have the respective meanings assigned to them in the LINE AGREEMENT. 

The LINE AGREEMENT provides, among other things, for acceleration (which in certain cases shall be automatic) of the maturity hereof upon the
occurrence of certain stated events, in each case without presentment, demand, protest or further notice of any kind, all of which are hereby expressly waived. 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

 

			
	 THORNE HEALTHTECH, INC.

		
	By:	 	 /s/ Scott S. Wheeler

		 	 Scott S. Wheeler

		 	 Chief Financial Officer

 SCHEDULE TO 

UNCOMMITTED AND REVOLVING CREDIT NOTE 

BORROWER: THORNE HEALTHTECH, INC. 

LINE AMOUNT: US$20,000,000.00 
  

															
	 Date
	 	 Bank’s
Reference
Number
	 	 Amount of

Loan
	 	 Maturity
Date
	 	 Applicable
Interest
Rate
	 	 Amount of
Principal
Paid
	 	 Unpaid
Balance of
Note
	 	 Notation
Made By:

 EXHIBIT B 

[Form of] 
 CERTIFICATE OF CHIEF
FINANCIAL OFFICER 
 The undersigned chief financial officer of THORNE HEALTHTECH, INC. (the “Borrower”) does hereby
certify to SUMITOMO MITSUI BANKING CORPORATION (the “Bank”) that: 
 1. This certificate (the
“Certificate”) is delivered in accordance with Section 5.01 of the UNCOMMITTED AND REVOLVING CREDIT LINE AGREEMENT dated as of February 12, 2021 between the Borrower and the Bank (as amended, modified, renewed or extended
from time to time, the “Line Agreement”). Capitalized terms used in this Certificate and not otherwise defined herein shall have the meanings ascribed to such terms in the Line Agreement. 

2. I have reviewed the annual financial report of the Borrower and its consolidated subsidiaries on a consolidated basis for the period ended
[_____] (the “Financial Report”), a complete copy of which is attached to this Certificate. 
 3. Based on my knowledge,
the Financial Report presents fairly in all material respects the financial condition and results of operations of the Borrower and its consolidated subsidiaries on a consolidated basis in accordance with GAAP consistently applied as of the end of
and for the period covered by the Financial Report. 
 4. Based on my knowledge, for the period covered by the Financial Report, and through
and including the date of this Certificate: 
 No Default or Event of Default has occurred. 

[or] 
 (a) The following
Default(s) or Event(s) of Default has/have occurred: 
 (b) The following action(s) has/have been taken or is/are proposed to be taken with
respect thereto: 
 IN WITNESS WHEREOF, the undersigned has executed this Certificate as of this _____ day of _____________, ________. 

 

			
	
		
	 By:
	 	 
		 	 Name:

		 	 Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]